Publications

Pancreatic cancer: a review (vol 326, pg 851, 2021)

W Park, A Chawla, EM O'Reilly

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, et al.

Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).

H Park, JC Bendell, WA Messersmith, DW Rasco, JS De Bono, ...

Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with …

V Florou, CS Floudas, A Maoz, AR Naqash, G Hildebrand, E Sokol, ...

Targeting DNA damage repair pathways in pancreas cancer

Crowley F, Park W, O'Reilly EM

388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors

J Bendell, W Messersmith, D Rasco, A Wang-Gillam, W Park, L Zhou, ...

75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer

D Bortone, S Vensko, S Entwistle, A Cogdill, A Monette, Y Najjar, R Sweis, ...

A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in …

DW Rasco, JC Bendell, A Wang-Gillam, W Park, EM O'Reilly, L Zhou, ...

Abstract CT247: A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with …

A Wang-Gillam, DW Rasco, W Park, E O'Reilly, W Messersmith, ...

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma

McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, … Park W, …

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, et al.

Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, et al.

Genetic algorithms to identify homologous recombination deficiency (HRD) in pancreas adenocarcinoma

W Park, J Chen, JF Chou, C Iacobuzio-Donague, N Riaz, EM O'Reilly

Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection

Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, …

Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers.

W Park, E Sokol, J Chen, KH Yu, D Khalil, JJ Harding, IH El Dika, N Riaz, ...

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, … Park W, …

P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets

NP Rudqvist, R Zappasodi, D Wells, V Thorsson, A Cogdill, A Monette, ...

Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK).

P Momtaz, CA O'Connor, JF Chou, M Capanu, KH Yu, AM Varghese, ...

Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC).

W Park, EM O'Reilly, J Furuse, F Kunieda, F Jie, HL Kindler

Reply to N. Fazio

O'Reilly EM, Park W, Kelsen DP

Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.

AM Varghese, I Singh, RR Singh, M Capanu, JF Chou, W Wong, ...

A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic …

J Bendell, D Rasco, W Park, L Zhou, A Galkin, D Slee, L Carter, D Nickle, ...

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, …

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, et al.

Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, … Park W, …

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, et al.

EP1. 01-61 iSEND Model as a Predictor of Efficacy in Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer: Fukushima Cohort

N Okabe, H Mine, H Takagi, M Watanabe, S Muto, T Hasegawa, Y Shio, ...

Extended mutational profiling by MSK-IMPACTTM identifies mutations predicting thromboembolic risk in patients with solid tumor malignancy

A Dunbar, K Bolton, SM Devlin, F Sanchez-Vega, J Gao, JV Mones, ...

Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.

V Florou, W Park, PJ Hosein, BA Wilky, JC Trent, G Lopes

Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review

Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM

Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC).

W Park, W Wong, KH Yu, AM Varghese, N Riaz, VP Balachandran, ...

MA07. 02 early change of dNLR is correlated with outcomes in advanced NSCLC patients treated with immunotherapy

L Mezquita, I Preeshagul, E Auclin, D Saravia, L Hendriks, H Rizvi, ...

Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer

Park W, Lopes G

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, …

(P09) Combined Use of Radiosurgery With Concurrent PD-1/PD-L1 Inhibition For Metastatic Brain Lesions of NSCLC

G Azzam, W Park, E Mellon, A Markoe, N Elsayyad, G Lopes, ...

A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).

BA Wilky, MM Trucco, D Kolonias, E Wieder, T Subhawong, A Rosenberg, ...

An inflammation paradox: Obesity vs. neutrophil-lymphocyte ratio in immunotherapy

W Park, V Florou, A Torres, D Saravia, S Algaze, G Lopes, ...

Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin

Algaze SD, Park W, Harrington TJ, Mudad R

Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection

Husnain M, Park W, Ramos JC, Johnson TE, Chan J, Dasari A, Mudad R, Hosein PJ

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, …

Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small …

L Mezquita, K Arbour, E Auclin, D Saravia, H Rizvi, L Hendriks, ...

Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab

Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, et al.

High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid …

V Florou, W Park, AE Torres, S Algaze, D Saravia, BA Wilky, JR Merchan, ...

MA19. 04 The Clinical Implication of Frameshift Indel Mutation Burden in Non-Small Cell Lung Cancer (NSCLC)

YK Chae, W Park, D Saravia, V Florou, S Chang, S Wang, L Chiec, ...

Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 …

D Saravia, N Okabe, W Park, D Kwon, L Mezquita, YK Chae, R Mudad, ...

P1. 01-68 Correlation of the lung immune prognostic index (LIPI) and PDL1 status with outcomes for immune checkpoint inhibitors in advanced NSCLC patients

L Mezquita, W Park, K Arbour, E Auclin, L Hendriks, D Planchard, ...

P1. 04-19 Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict survival after immunotherapy in non-small cell lung cancer

M Oh, D Saravia, S Agte, A Rahbari, W Park, G Lopes, Y Chae

P2. 01-82 Neutrophil-to-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors

D Saravia, S Agte, N Okabe, W Park, D Kwon, R Mudad, H Suzuki, ...

Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model.

W Park, L Mezquita, N Okabe, D Kwon, D Saravia, YK Chae, A Desai, ...

The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review

Farhat F, Torres A, Park W, de Lima Lopes G, Mudad R, Ikpeazu C, Abi Aad S